204 results
8-K
EX-99.1
CYTK
Cytokinetics Inc
13 Dec 10
Other Events
12:00am
at 6 hours after dosing with CK-2017357, based on a Global Assessment in which the patient and the investigator each independently assessed whether … , the relationship between the likelihood of a “better” assessment and the CK-2017357 plasma concentration was nominally statistically significant both
8-K
CYTK
Cytokinetics Inc
31 Mar 23
Other Events
7:33am
, approximately 460 patients had been randomized and over 200 had reached the 24-week assessment of the trial endpoints. This interim analysis … weeks in ALSFRS-R. Secondary endpoints included combined assessment of ALSFRS-R total score, time to onset of respiratory insufficiency and survival
8-K
EX-99.1
CYTK
Cytokinetics Inc
30 Nov 11
CK-2017357 Demonstrated To Be Well-Tolerated in First Cohort of Ongoing Clinical Trial
12:00am
revised version as the ALSFRS-R, has become the most frequently used assessment of activities of daily living in ALS trials. The authors of this poster … , all of whom were involved in the original development of the assessment, highlighted that the ALSFRS and the ALSFRS-R are reliable and reproducible
S-8
EX-23.1
CYTK
Cytokinetics Inc
14 Apr 06
Registration of securities for employees
12:00am
Statement on Form S-8 of our report dated March 8, 2006, relating to the financial statements, management’s assessment of the effectiveness of internal
8-K
EX-99.1
CYTK
Cytokinetics Inc
18 Apr 11
Presentation Included Additional Results Arising from Recent Analyses Relating to Muscle Strength at 24 Hours and Concentration-Response Relationships
12:00am
in the patients’ overall status at 6 hours after dosing with CK-2017357, based on a Global Assessment in which the patient and the investigator each independently … ). In addition, the relationship between the likelihood of a “better” assessment and the CK-2017357 plasma concentration was nominally statistically
8-K
EX-99.1
v1nl7j
22 Apr 09
Cytokinetics Announces Non-clinical Data Relating to GSK-923295 Presented at the 2009 American Association of Cancer Research Annual Meeting
12:00am
8-K
EX-99.1
9fqgg6vg31bvuqcce
2 Jun 11
Clinical Trial Demonstrates Translation of Mechanism of Action of Novel Drug Candidate in 2nd Disease Population
12:00am
8-K
29f kvbq3fecprdr3
11 Oct 22
Other Events
7:31am
8-K
yj26q4x t7ncnpvxv
8 Dec 22
Other Events
7:31am
S-8
EX-23.1
e60a1b8vedqn2omttv6g
11 Aug 06
Registration of securities for employees
12:00am
S-3MEF
EX-23.1
523vrn8xwqr
30 Oct 06
Registration of additional securities for an S-3
12:00am
8-K
EX-10.70
hcata kgtq87mxyj
19 May 09
Cytokinetics Announces Registered Direct Common Stock Offering of $ 14.0 Million
12:00am
8-K
EX-99.1
nghqmey 99koxlso
7 Jun 06
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2006 Annual Meeting of the American Society of Clinical Oncology
12:00am
8-K
EX-99.1
p6djbdszilwggeo0
4 Jan 11
Cytokinetics Announces Opening of a Phase Iia “Evidence of Effect” Clinical Trial of CK-2017357 In Patients with Myasthenia Gravis
12:00am
8-K
EX-99.1
n8gbs
6 Aug 20
Cytokinetics Reports Second Quarter 2020 Financial Results
4:00pm
8-K
nosfqt rdfll6
22 Apr 09
Cytokinetics Announces Non-clinical Data Relating to GSK-923295 Presented at the 2009 American Association of Cancer Research Annual Meeting
12:00am
8-K
4fbf1
24 Feb 21
Compensation Information for the Company’s Named Executive Officers
7:30am